Anti-DPPX encephalitis: Prominent nystagmus reflected by extraocular muscle FDG-PET avidity
Citation Manager Formats
Make Comment
See Comments

A 43-year-old Caucasian man developed persistent nystagmus after 10 months of weight loss, diarrhea, insomnia, and 5 months of agitation, memory impairment, and vision changes consisting of nystagmus and double vision. Ocular motor examination demonstrated left-beating nystagmus (LBN), upbeating nystagmus (UBN), and torsional (toward the left ear) nystagmus components (video at Neurology.org/nn), as well as a left hypertropia from a skew deviation. There was also gaze-evoked nystagmus (GEN) horizontally. General neurologic examination revealed postural tremor in his arms, brisk reflexes, mild dysmetria with finger to nose, and wide-based gait. Detailed neurocognitive testing demonstrated deficits in recall and attention. He had previously been healthy, and his family history was notable only for multiple sclerosis in his brother. Brain MRI showed no abnormalities, and CSF studies showed elevated protein. A broad screen for infections, toxins, and systemic autoimmune disorders was negative. Peripheral blood cell counts were normal. Whole-body 18-fluoro-deoxyglucose PET (18FDG-PET-CT) did not reveal a malignancy, but showed asymmetric avidity of the extraocular muscles (figure). Testing for neuronal autoantibodies revealed a serum dipeptidyl-peptidase-like protein-6 (DPPX) antibody IgG titer of 1:15,360 (Neuroimmunology Laboratory, Mayo Clinic), providing evidence for immune-mediated encephalitis. DPPX antibody from CSF was not tested because of inadequate sample quantity before the initiation of treatment.
F18-FDG-PET/CT demonstrates normal size of extraocular muscles but markedly asymmetric increased FDG activity localizing to the left medial rectus and right lateral rectus (A and B, arrows), and inferior recti bilaterally (C and D, arrows).
He was treated with IV methylprednisolone, plasma exchange, and rituximab, with improvement in hyperreflexia, gait, memory, sleep, mood, and appetite. His nystagmus and skew deviation also improved markedly (video). The UB-torsional nystagmus (which had an LBN component) seen at presentation was believed to result mainly from either semicircular canal (SCC) pathway imbalance at the level of the medulla or, in light of the skew deviation, disruption of the utricle-ocular motor pathways. In support of the latter, in follow-up months later, spontaneous downbeat nystagmus (DBN) was seen, and it was noted that changes in head orientation relative to gravity (head tilt and supine position) transitioned his DBN to UBN, a feature that can be seen with utricle pathway damage.1 Overall, in our patient's case, ocular motor signs would be best explained by involvement of the perihypoglossal nuclei (UBN and GEN), paramedian tract cell groups, or their connections with the vestibulocerebellum (DBN), and vestibular nuclei (causing SCC and utricle imbalance, right more than left-sided dysfunction given skew deviation with left hypertropia and LBN).
DPPX, a recently recognized neuronal surface autoantigen, is a regulatory subunit of the voltage-gated Kv4.2 potassium channel complex expressed on neuronal dendrites and soma, dysfunction of which may result in neuronal hyperexcitability.2,–,4 Kv4.2 channels and DPPX proteins are distributed throughout the nervous and enteric systems, including the cortex, cerebellum, brainstem, and myenteric and submucous plexus.2,3,5 The widespread expression of DPPX is believed to underlie the broad manifestations of anti–DPPX-associated disease, including neurocognitive deficits, sleep disturbance, central hyperexcitability, and diarrhea. The majority of patients described have gastrointestinal symptoms, including diarrhea, constipation, and weight loss, and these symptoms as well as neurologic symptoms may present insidiously, thus making diagnosis challenging. Eye movement disturbances are common. Of 20 seropositive anti-DPPX patients, diplopia, oscillopsia, or blurred vision was reported in 8 patients, with one case of upbeat-torsional nystagmus.3 Additional described visual disturbances include saccadic pursuit gaze movements in all directions; spontaneous downbeat and gaze-evoked nystagmus, broken pursuit, and incomplete suppression of vestibulo-ocular reflex on fixation; and broken pursuit and GEN with diplopia on lateral gaze.3,6 Cerebellar and pontine targets by autoantibodies resulting in CNS hyperexcitability may underlie these ocular manifestations.
Although FDG-PET is often used to assess malignancy in patients with autoimmune encephalitis, may demonstrate abnormalities in brain metabolism, and has been reported to reflect muscle hyperactivity in other autoimmune neurologic conditions, little is known of PET findings in anti-DPPX encephalitis.6 The FDG-PET in our case did not show evidence of malignancy, but did demonstrate asymmetric metabolism in extraocular muscles correlating with the slow (pathologic) phases of nystagmus. In particular, FDG-PET showed increased FDG activity in the left medial rectus, right lateral rectus, and bilateral inferior recti, correlating with the slow phases of his horizontal (LB) and vertical (UB) nystagmus, respectively. Although FDG-PET correlates of nystagmus have not been previously characterized, increased avidity of bilateral medial recti has been reported in a case of convergence spasm due to brain tumor.7
Overall, our case highlights the prominent eye movement abnormalities that can occur in the setting of anti-DPPX encephalitis, points to specific pontine and medullary nuclei that may be impacted, and highlights that FDG-PET can demonstrate correlates of nystagmus in this disease.
Footnotes
Supplemental data at Neurology.org/nn
Author contributions: Leana Doherty: drafting and revising of the manuscript and selecting initial images. Daniel Gold: filming and video acquisition, editing of the manuscript, and video legend. Lilja Solnes: selecting and editing of images. John Probasco: editing of the manuscript. Arun Venkatesan: critical editing of the manuscript.
Study funding: No targeted funding reported.
Disclosure: L. Doherty reports no disclosures. D. Gold is on the editorial board for Current Treatment Options in Neurology; co-section editor for Neuro-ophthalmology and Otology; and consulted for WellPoint Insurance. L. Solnes reports no disclosures. J. Probasco served on the editorial board and is associate editor for The Neurohospitalist and is Editor-in-Chief for NEJM Journal Watch Neurology. A. Venkatesan served on the scientific advisory board for MedImmune; served as a medical expert for the U.S. Government Vaccine Injury Compensation Program; received research support from NIH; and served as a medical expert for Carnival Cruise Lines. Go to Neurology.org/nn for full disclosure forms. The Article Processing Charge was funded by the authors.
- Received March 13, 2017.
- Accepted in final form April 4, 2017.
- Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
References
- 1.↵
- 2.↵
- 3.↵
- Tobin WO,
- Lennon VA,
- Komorowski L, et al
- 4.↵
- Piepgras J,
- Höltje M,
- Michel K, et al
- 5.↵
- 6.↵
- Stoeck K,
- Carstens PO,
- Jarius S, et al
- 7.↵
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Topics Discussed
Alert Me
Recommended articles
-
Article
Central paroxysmal positional nystagmusCharacteristics and possible mechanismsJeong-Yoon Choi, Ji Hyun Kim, Hyo Jung Kim et al.Neurology, May 08, 2015 -
Article
Capturing acute vertigoA vestibular event monitorAllison S. Young, Corinna Lechner, Andrew P. Bradshaw et al.Neurology, May 15, 2019 -
Article
Nucleus prepositus hypoglossi lesions produce a unique ocular motor syndromeSung-Hee Kim, David S. Zee, Sascha du Lac et al.Neurology, October 12, 2016 -
Article
Ictal downbeat nystagmus in Ménière diseaseA cross-sectional studySun-Uk Lee, Hyo-Jung Kim, Jeong-Yoon Choi et al.Neurology, August 14, 2020